Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids* , as well as clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.
*in collaboration with AbbVie
*in collaboration with AbbVie
Location: United States, California, San Diego
Employees: 501-1000
Founded date: 1992
Investors 1
| Date | Name | Website |
| 07.07.2021 | Internatio... | ibtplc.com |
Mentions in press and media 34
| Date | Title | Description |
| 17.08.2026 | Cramer’s lightning round: Buy Uber | Monday - Friday, 6:00 - 7:00 PM ET It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed. Uber: “Uber is one great long-term stock. I... |
| 14.07.2026 | Американская Vertex Pharmaceuticals покупает биофармацевтическую Crinetics за $10 млрд | Американская биотехнологическая компания Vertex Pharmaceuticals, специализирующаяся на разработке инновационных препаратов для лечения тяжелых и редких заболеваний, договорилась о приобретении американской биофармацевтической компании Crine... |
| 18.05.2026 | Neurocrine Biosciences: $2.9 Billion Soleno Therapeutics Acquisition Expands Rare Disease Portfolio | Neurocrine Biosciences announced the completion of its acquisition of Soleno Therapeutics, strengthening its endocrinology and rare disease portfolio with the addition of VYKAT XR, the first and only approved treatment for hyperphagia in pa... |
| 06.04.2026 | Neurocrine Biosciences Acquires Soleno Therapeutics, for Approx. 2.9 Billion | Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a San Diego, California-based provider of developer of pharmaceutical treatments for neurological, endocrine, and psychiatric disorders, acquired Soleno Therapeutics, Inc. (Nasdaq: SLNO), a Redwo... |
| 06.04.2026 | Американская биофармкомпания Neurocrine покупает разработчика редких препаратов Soleno за $2,9 млрд | Американская биофармацевтическая компания Neurocrine Biosciences приобретает разработчика препаратов для редких заболеваний Soleno Therapeutics за $2,9 млрд наличными, сообщили компании в понедельник. Сделка знаменует расширение Neurocrine,... |
| 06.04.2026 | Supplier.io Acquires TealBook | Supplier.io, a Chicago, Illinois-based provider of supplier intelligence, acquired TealBook, a Toronto, Ontario-based provider of vendor master data cleansing. The amount of the deal was not disclosed. With the deal, Supplier.io, will expan... |
| 05.04.2026 | Daily Stock Market Live S&P 500 futures nudge higher on report Iran and U.S. are trying for ceasefire: Live updates | S&P 500 futures ticked higher on Monday following a winning week as oil prices fell slightly, with traders weighing the odds that the U.S.-Iran war could end soon. Futures tied to the broad market index ticked up 0.1%, while Nasdaq-100 ... |
| 25.01.2026 | Immedica Completes Major Rare Disease Acquisition, Expands Global Endocrinology Footprint | Immedica Pharma finalized its $65 million acquisition of Neurocrine Group Limited. This strategic move adds Alkindi and Efmody, critical hydrocortisone therapies for rare adrenal conditions, to Immedica's portfolio. The deal establishes rar... |
| 21.01.2026 | Immedica completes acquisition of Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business | Immedica completes acquisition of Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business Wed, Jan 21, 2026 15:45 CET Report this content Portfolio includes global rights to Alkindi® (hydrocortisone) and global r... |
| 08.01.2026 | Immedica to acquire Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business | Immedica to acquire Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business Thu, Jan 08, 2026 18:00 CET Report this content Portfolio includes global rights to Alkindi® (hydrocortisone) and global rights ex-US to... |
Show more